PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsVolanesorsen
Volanesorsen
Waylivra (volanesorsen) is an oligonucleotide pharmaceutical. Volanesorsen was first approved as Waylivra on 2019-05-03. It has been approved in Europe to treat hyperlipoproteinemia type i.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
hereditary congenital and neonatal diseases and abnormalitiesD009358
nutritional and metabolic diseasesD009750
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
premasol - sulfite-free (amino acid)ANDA2022-08-04
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C10: Lipid modifying agents
— C10A: Lipid modifying agents, plain
— C10AX: Other lipid modifying agents in atc
— C10AX18: Volanesorsen
HCPCS
No data
Clinical
Clinical Trials
929 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———24——21339
Type 2 diabetes mellitusD003924EFO_0001360E1129271836
ObesityD009765EFO_0001073E66.923542435
Hiv infectionsD015658EFO_0000764B2044122527
Insulin resistanceD007333HP_0000855E88.819———12021
Kidney transplantationD016030——1618116
Breast neoplasmsD001943EFO_0003869C504321414
Non-small-cell lung carcinomaD002289——1941114
GoutD006073EFO_0004274M10—164213
Dry eye syndromesD015352—H04.1211—2812
Show 76 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Colorectal neoplasmsD015179——293—114
Precursor cell lymphoblastic leukemia-lymphomaD054198—C91.0441—210
Covid-19D000086382—U07.1342—19
HyperuricemiaD033461HP_0002149—122—49
InfectionsD007239EFO_0000544—224——8
MalnutritionD044342EFO_0008572E40-E46—12—58
Pancreatic neoplasmsD010190EFO_0003860C25322——7
OverweightD050177—E66.31—1—57
LeukemiaD007938—C95142——7
HypertriglyceridemiaD015228EFO_0004211—122—27
Show 64 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myelodysplastic syndromesD009190—D4655——111
Myeloid leukemia acuteD015470—C92.034——18
Knee osteoarthritisD020370EFO_0004616M1711——67
Hematologic neoplasmsD019337——23———4
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_0000340—22———4
Stomach neoplasmsD013274EFO_0003897C16—2——24
MelanomaD008545——13———4
Hepatitis bD006509——13———4
HyperglycemiaD006943HP_0003074R73.911——34
Cognitive dysfunctionD060825HP_0001268G31.8412——13
Show 71 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Acute painD059787—R521———34
AgingD000375GO_0007568R41.811———34
Chronic obstructive pulmonary diseaseD029424EFO_0000341J44.91———34
HypercholesterolemiaD006937HP_0003124—1———34
Myelomonocytic leukemia chronicD015477—C93.13————3
AnemiaD000740HP_0001903D64.91———12
Peptic ulcerD010437HP_0004398K272————2
NeuroblastomaD009447EFO_0000621—2————2
GlioblastomaD005909EFO_0000515—2————2
Gastric bypassD015390EFO_0005244—1———12
Show 50 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PhenylketonuriasD010661—E70.0————77
ExerciseD015444EFO_0000483—————55
PregnancyD011247EFO_0002950Z33.1————55
HyperlipidemiasD006949HP_0003077E78.5————33
SarcopeniaD055948EFO_1000653M62.84————33
SepsisD018805HP_0100806A41.9————33
SleepD012890GO_0030431—————33
Critical illnessD016638——————22
Macular edemaD008269——————22
AstigmatismD001251EFO_0004222H52.2————22
Show 119 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameVolanesorsen
INNvolanesorsen
Description
Volanesorsen, sold under the brand name Waylivra, is a triglyceride-reducing drug. It is a second-generation 2'-O-methoxyethyl (2'-MOE) chimeric antisense therapeutic oligonucleotide (ASO) that targets the messenger RNA for apolipoprotein C3 (apo-CIII).
Classification
Oligonucleotide
Drug classantisense oligonucleotides
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL3544994
ChEBI ID—
PubChem CID122409770
DrugBankDB15067
UNII ID2O4BE0K238 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Waylivra – Ionis Pharmaceuticals
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 384 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
12 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use